FDA Warning Letter Hits Amphastar Subsidiary for Manufacturing Compliance
AMPH sits 20% above its 52-week low of $16.645.
Summary
Amphastar Pharmaceuticals' subsidiary received an FDA Warning Letter on July 2, 2026, for CGMP violations at its California manufacturing facility, concerning the facility's manufacturing practices. This regulatory action follows the company's Q1 2026 10-Q filing, which had previously noted an FDA "Official Action Indicated" classification for a facility. Although no immediate product cessation or recall was ordered, the letter highlights serious compliance issues that could lead to further regulatory action and operational disruptions for the company. Amphastar is currently implementing corrective actions and is required to submit a comprehensive remediation plan to the FDA.
At the time of this announcement, AMPH was trading at $20.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $885.4M. The 52-week trading range was $16.65 to $31.26. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.